Russia has also faced criticism for not completing all phases of experimental testing. Experts from within the country and abroad also warned against widespread use of the vaccine till its completion. At the same time, the administration, ignoring suggestions, started giving vaccines to at-risk groups, including health workers working on the advance fronts. Alexander Gintzberg, head of the Gamalaya Institute that developed the vaccine, said last week that more than one and a half million people in Russia had been given vaccine doses.
Precaution after vaccine
ICU specialist Alexander Justsepine also took the vaccine dose in Voronezh, about 500 km from Moscow. He said that despite taking the vaccine, he is taking precaution because the study about its effect has not been completed yet. The UK approved Pfizer’s vaccine on 2 December. After this, Russia also started vaccination on a large scale due to the fear of being left behind in the competition for vaccine manufacture.
Being given to people aged 18-60
Russia approved the vaccines developed in its country only after clinical trials on a few dozen people. The vaccine makers named it ‘Sputnik-V’. In this way, its reference was linked to the first satellite left by the Soviet Union in 1957 during the Cold War. In the UK, vaccine doses are first given to the elderly, while ‘Sputnik-V’ is being given to people between the ages of 18 and 60.
91% effective vaccine
Vaccine manufacturers said the study showed that the sputum vaccine was 91 percent effective. This result was derived from a study conducted on about 23,000 participants, while Western countries included more people, people of different backgrounds, ages, in the test. Levada Center, an independent survey organization in Russia, conducted an opinion poll in October, with 59 per cent saying they would not want to take the vaccine despite being offered it. Talking to some health workers and teachers led to the fact that they did not want to take the vaccine due to not being tested properly.